Renal cell cancer 9 1 0 2 High incidence in North America and - PowerPoint PPT Presentation

Renal cell cancer 9 1 0 2 • High incidence in North America and s Western Europe s a l • Heterogeneous disease with c r different histological subtypes e t and disease biology s a M • Local treatment by surgery, role for surgery in oligometastatic disease R B • Treatment by TKI, VEGF and Checkpoint E Inhibition E O M S E - O S E New Cases 948 Deaths 448 data from http://www.globocan.iarc.fr 2012

Renal Cell Cancer in Europe 2018 9 1 0 Incidence 2 Mortality s s a l c r e t s a M R B E E O M S E - O S E https://ecis.jrc.ec.europa.eu

9 1 0 2 s s a l c r e t s a M R B E E O M S E - O S E Cohen & McGovern NEM 2005;353:2477

9 1 0 2 s s a l c r e t s a M R B E E O M S E - O S E

Metastastic Renal Cell Cancer 9 1 0 2 s s a Renal Cancer Drug Therapy 2018 l c r e t s a Metastatic Metastatic Metastatic M R Axitinib Sunitinib Everolimus B Nivolumab Pazopanib Sorafenib E E Cabozantinib O Lenvatinib & M Temsirolimus Everolimus S IFN & Beva E Everolimus HD IL-2 - Sorafenib O S E

9 1 0 2 s s a l c r e t s a Local & locally advanced M R B E E O M S E - O S E

Male, 64 years presents with flank pain 9 1 0 2 s s Large right-sided mass, no distant metastases a l c r e t s a M R B E E O M S E - O S E

Metastatic Renal Cell Cancer 9 1 0 2 s s a Renal Cancer Drug Therapy 2018 l c r e t s a Metastatic Metastatic Metastatic M R Axitinib Sunitinib Everolimus B Nivolumab Pazopanib Sorafenib E E Cabozantinib O Lenvatinib & M Temsirolimus Everolimus S IFN & Beva E Everolimus HD IL-2 - Sorafenib O S E

Metastatic Renal Cell Cancer 9 1 0 2 s s a Renal Cancer Drug Therapy 2018 l c r e t s a Metastatic Metastatic Metastatic M R Axitinib Sunitinib Everolimus B Nivolumab Pazopanib Sorafenib E E Cabozantinib O Lenvatinib & M Everolimus S Temsirolimus E IFN & Beva Everolimus - HD IL-2 Sorafenib O S E

9 1 0 2 s s a l c r e t s a Metastatic M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s a M R B E E O M S E Prognosis ? - O S E

9 1 0 2 s s a l c r e t s International mRCC Database Consortium (IMDC) Criteria<br /> a M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s IMDC Criteria in First-Line Targeted Therapy a M R B E E O M S E - O S E Presented By Daniel Heng at 2018 ASCO Annual Meeting

9 1 0 2 s s a l c r e t s IMDC Criteria in Second-Line Targeted Therapy a M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s IMDC Criteria in Third-Line Targeted Therapy a M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s IMDC in Non-clear Cell RCC <br />Kroeger N et al Cancer 2013 a M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s a M R B E E O M S E Management Primary ? - O S E

9 1 0 2 s s a l c r e t s CARMENA: Prospective, multicenter, open-label, randomized, phase 3 non-inferiority study a M R B E E O M S E - O S E Presented By Arnaud Mejean at 2018 ASCO Annual Meeting

9 1 0 2 s s a l c r e t s Patient population a M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s Overall <br />survival (ITT) a M R B E E O M S E - O S E

9 1 0 2 s s a l c r e t s a M R B E E O M S E - O S E NEJM 2018; 379:417

9 1 0 2 s s a l c r e t s a M R B E E O M S E First-line treatment ? - O S E

Metastatic Renal Cell Cancer 9 1 0 2 s s a Renal Cancer Drug Therapy 2018 l c r e t s a Metastatic Metastatic Metastatic M R Nivolumab Sunitinib Everolimus B Axitinib Pazopanib Sorafenib E E Cabozantinib O Lenvatinib & M Everolimus Temsirolimus S IFN & Beva Everolimus E HD IL-2 Sorafenib - O S E

9 1 0 2 s s a l c r e t s a M R B E E O M S E - O S E NEJM 2013;369:722

Metastatic Renal Cell Cancer 9 1 0 2 s s a Renal Cancer Drug Therapy 2018 l c r e t s a Metastatic Metastatic Metastatic M R Nivolumab Sunitinib Everolimus B Axitinib Pazopanib Sorafenib E E Cabozantinib O Lenvatinib & M Everolimus Temsirolimus S IFN & Beva Everolimus E HD IL-2 Sorafenib - O S E

9 1 0 2 s s a l c r e t s a M R B E E O M S E - O S E Escudier et al ESMO 2017 LBA5

24.980.- CHF per 6 weeks 9 1 5.476.- CHF per 6 weeks 0 2 s s a l c r e t s a M R B E E O M S E - O S E

9 23.377.- CHF per 6 weeks 1 0 5.476.- CHF per 6 weeks 2 s s a l c r e t s a M R B E E O M S E - O S E

21.307.- CHF per 6 weeks 9 1 5.476.- CHF per 6 weeks 0 2 s s a l c r e t s a M R B E E O M S E - O S E

Metastatic Renal Cell Cancer 9 1 0 2 s s a Renal Cancer Drug Therapy 2019 l c r e t s a Metastatic Metastatic Metastatic M R ? Axitinib Sunitinib ? Everolimus B Pazopanib ? Nivolumab ? Sorafenib E Nivo & Ipi E ? Cabozantinib Pem & Axitinib O ? Lenvatinib & Ave & Axitinib M Everolimus Atezo & Bev S E ? Everolimus - ? Sorafenib O S E 12-15 months ???

Plenary Session 9 1 0 2 s s a l c r e t s a M R B E E O M S E - 2019 O S E

Plenary Session 9 1 0 2 s s a l c r e t s a M R B E E O M S E - O S E

Renal cell cancer 9 1 0 2 High incidence in North America and - PowerPoint PPT Presentation

Renal cell cancer 9 1 0 2 High incidence in North America and s Western Europe s a l Heterogeneous disease with c r different histological subtypes e t and disease biology s a M Local treatment by surgery, role for

VHL and clear cell Renal Cell Carcinoma Gene expression profiles in renal cell VHL syndrome

Comprehensive Molecular Characterization Papillary Renal Cell Carcinoma The Cancer Genome Atlas

Influence of Gene Expression on progression of Renal Cell Carcinoma Jong Y. Park, PhD, MPH, MS.

5/25/2017 EPITHELIAL KIDNEY TUMORS: RENAL CELL CARCINOMA EPIDEMIOLOGY (2016) NEW ENTITIES AND

Cytoreductive nephrectomy in renal cell carcinoma: still required in the combined targeted and

Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD

Chromophobe Renal Cell Carcinoma TCGA KICH AWG Chairs: Chad Creighton, W. Kim Rathmell

Percutaneous ablation of renal cell carcinoma Where do we stand now? Sanja Stojanovi, Spasi

CCLE Cancer Cell Line Encyclopedia Data 947 cancer cell lines with: 1600 genes from

Modeling cell life and cell death in cancer Andrei Zinovyev Computational Systems Biology of

RENAL CELL CARCINOMA IN CHILDREN AND ADOLESCENTS A RETROSPECTIVE ANALYSIS OF A COOPERATIVE

Stereotactic radiotherapy and target therapy for oligometastatic patients with renal cell

Clear Cell Cancer Mary McCormack - NCRI GCIG Lisbon 2016 Ovarian Clear Cell Cancer Rare

Molecular Subtypes of Renal Cell Carcinoma Deepika Sirohi, MD University of Utah and ARUP

Molecular Subtypes of Renal Cell Carcinoma Deepika Sirohi, MD University of Utah and ARUP

A PHASE I STUDY OF INTRAVENOUS RECOMBINANT HUMAN IL-15 (rhIL-15) IN ADULTS WITH METASTATIC

Unilateral Radiotherapy in Node Positive Patients with Lateralized Tonsillar Carcinoma W. L.

Data driven Ontology Alignment Data driven Ontology Alignment Nigam Shah nigam@stanford.edu

Mining Huge Collections of Genomics Datasets for Genes Controlling Complex Traits from Humans to

FNAB : AN ATTRACTIVE ALTERNATIVE TO DIAGNOSIS BREAST CARCINOMA F. T. ANDRIAMAMPIONONA , L. C. A.

Why could patients with HF and T2DM benefit from SGLT2i? Subodh Verma, MD Ontario, Canada May

February 22, 2017 Presenters Heather Holsey Josiah Mueller Rhya Ghose 2 Disclaimer

Identifying Hazards in the Cardiac Operating Room* Event-driven, nonlinear, unpredictable

Multi-Input Cardiac Image Super-Resolution using Convolutional Neural Networks Ozan Oktay, Wenjia